Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
NCT01336023 on ClinicalTrials.gov · last registry update 2018-02-19
An unusually large phase 3: 1,663 participants, more than double the 424 typical for the stage. The sponsor logged completion for 24 May 2012. Primary outcome, as filed: Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P3
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 1,663
- Started
- 2011-05-23
- Primary completion
- 2012-05-24 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.
Conditions studied
Diabetes · Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.